Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1626 1692
This examiner grants 68% of resolved cases
Madeline E. Braun serves in Tech Center 1600 and Art Unit 1624. The examiner has a record of 147 resolved cases. These cases result in an allowance rate of 68.0%, which indicates the frequency of grants for applications reaching a final disposition. The median days to allowance is 1350, providing a benchmark for the expected duration of the prosecution cycle. Practitioners can use the 68.0% allowance rate to assess the likelihood of a successful outcome when an application is assigned to this examiner.
The data shows an interview lift of 25.7%. This lift suggests that interviews are an effective tool for communication, potentially improving the 68.0% allowance rate. The 1350-day median to allowance reflects the pace of the examination process in Art Unit 1624. Practitioners should consider these metrics when advising clients on the timeline and probability of grant. The consistency seen across 147 resolved cases offers a predictable environment for patent prosecution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706551 | USES OF RHODOQUINONE FOR THE TREATMENT OF DISEASE | Non-Final OA | University of Massachusetts |
| 18558812 | CO-CRYSTAL OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR PREPARING SAME | Non-Final OA | LG CHEM, LTD. |
| 18861291 | PENEM ANTIBACTERIALS AGAINST MYCOBACTERIAL PATHOGENS AND D,D- AND L,D TRANSPEPTIDASES | Non-Final OA | The Johns Hopkins University |
| 18866801 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18710037 | METHOD OF TREATING CANCER ASSOCIATED WITH RAS MUTATION | Non-Final OA | The United States Government as Represented by The Department of Veterans Affairs |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18490967 | HETEROCYCLIC COMPOUNDS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18713496 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18274549 | C PRIME AGENTS FOR TREATING METABOLIC DISORDERS | Non-Final OA | The University of Toledo |
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | Non-Final OA | Amicus Therapeutics, Inc. |
| 18904564 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. |
| 17634414 | PHYTOCANNABINOIDS FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, DYSLIPIDEMIA, AND TYPE 2 DIABETES | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 18678103 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | Non-Final OA | ATROGI AB |
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | Non-Final OA | Cardiff Oncology, Inc. |
| 17596486 | SMARCA DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 18546234 | TREATMENTS OF PRADER-WILLI SYNDROME | Final Rejection | Neuren Pharmaceuticals Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy